The efficacy of cariprazine in chronic schizophrenia – post hoc analyses of phase II/III clinical trials

INTRODUCTION: Chronic schizophrenia patients are experiencing persistent and severe illness for more than 15-20 years and are usually suffering from long-term negative symptoms. Cariprazine, a novel D(3)-D(2) partial agonist has been proven to be effective in the treatment of acute schizophrenia, ho...

Descripción completa

Detalles Bibliográficos
Autores principales: Falkai, P., Dombi, Z., Acsai, K., Barabássy, Á., Németh, G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2022
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9567052/
http://dx.doi.org/10.1192/j.eurpsy.2022.822

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9567052/
http://dx.doi.org/10.1192/j.eurpsy.2022.822

Ejemplares similares